Perspectives in the Treatment of or Mutated Metastatic Colorectal Cancer Patients.
作者信息
Rosati Gerardo, Aprile Giuseppe, Basile Debora, Avallone Antonio
机构信息
Medical Oncology Unit, "S. Carlo" Hospital, Potenza, Italy.
Medical Oncology Unit, "San Bortolo" Hospital, Vicenza, Italy.
出版信息
Front Oncol. 2021 Mar 2;11:602596. doi: 10.3389/fonc.2021.602596. eCollection 2021.
Abstract
摘要
相似文献
1
Perspectives in the Treatment of or Mutated Metastatic Colorectal Cancer Patients.治疗KRAS或NRAS突变转移性结直肠癌患者的观点。
Front Oncol. 2021 Mar 2;11:602596. doi: 10.3389/fonc.2021.602596. eCollection 2021.
2
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.RAS/PIK3CA/BRAF肿瘤突变作为转移性结直肠癌患者一线贝伐单抗化疗反应预测指标的回顾性研究。
BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6.
3
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.表皮生长因子受体（EGFR）基因拷贝数可预测RAS野生型及RAS/ BRAF/PIK3CA野生型转移性结直肠癌患者对抗表皮生长因子受体治疗的反应。
Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.
4
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.在组织检测 RAS 野生型的晚期结直肠癌患者中，游离 DNA 中的 RAS 和 BRAF 突变可预测西妥昔单抗单药治疗的疗效。
Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30.
5
Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.用于改善转移性结直肠癌患者抗表皮生长因子受体（EGFR）治疗选择的纳米流体数字PCR及RAS和BRAF基因分型扩展技术
Mol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.
6
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.BRAF 突变型转移性结直肠癌中国患者的临床病理特征及治疗疗效：一项回顾性观察研究
Chin J Cancer. 2017 Oct 16;36(1):81. doi: 10.1186/s40880-017-0247-y.
7
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).先前接受 FOLFOXIRI 联合贝伐珠单抗治疗的伴有任何 RAS 或 BRAF 突变的转移性结直肠癌患者中使用单药regorafenib（PREVIUM 试验）。
Oncologist. 2018 Nov;23(11):1271-e128. doi: 10.1634/theoncologist.2018-0316. Epub 2018 Aug 17.
8
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.根据肿瘤RAS和BRAF突变状态，FOLFOX4联合西妥昔单抗用于先前未治疗的转移性结直肠癌患者：CECOG/CORE 1.2.002研究的更新分析
Clin Colorectal Cancer. 2015 Jun;14(2):91-8. doi: 10.1016/j.clcc.2014.12.003. Epub 2014 Dec 24.
9
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.转移性结直肠癌患者的健康相关生活质量与全身炎症反应及 RAS 和 BRAF 突变状态的关系。
Eur J Cancer. 2017 Aug;81:26-35. doi: 10.1016/j.ejca.2017.04.026. Epub 2017 Jun 6.
10
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.BRAF 和 K-RAS 突变型结直肠癌的临床病理和蛋白特征及其对预后的影响。
Int J Cancer. 2010 Jul 15;127(2):367-80. doi: 10.1002/ijc.25042.
引用本文的文献
1
, and Mutational Profile of Colorectal Cancer in a Series of Moroccan Patients.摩洛哥患者系列中的结直肠癌的突变特征。
Cancer Control. 2024 Jan-Dec;31:10732748241262179. doi: 10.1177/10732748241262179.
2
RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.根据 HER2 扩增情况，原发性结直肠癌中的 RAS/RAF 突变和微卫星不稳定性状态。
Sci Rep. 2024 May 19;14(1):11432. doi: 10.1038/s41598-024-62096-x.
3
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy.结直肠癌异质性及其对精准医学和治疗效果的影响。
Biomedicines. 2022 Apr 30;10(5):1035. doi: 10.3390/biomedicines10051035.
本文引用的文献
1
KRAS Inhibition with Sotorasib in Advanced Solid Tumors.索托拉西布治疗晚期实体瘤的 KRAS 抑制作用。
N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
2
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. upfront FOLFOXIRI 联合贝伐珠单抗和进展后再引入与 mFOLFOX6 联合贝伐珠单抗后序贯 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌患者（TRIBE2）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
3
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply.恩考芬尼、比美替尼和西妥昔单抗用于BRAF V600E突变型结直肠癌。回复。
N Engl J Med. 2020 Feb 27;382(9):877-878. doi: 10.1056/NEJMc1915676.
4
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.结直肠癌的预后和预测分子生物标志物：更新与挑战
Cancers (Basel). 2020 Jan 30;12(2):319. doi: 10.3390/cancers12020319.
5
Two new agents target KRAS G12C.两种新型药物靶向KRAS G12C。
Nat Rev Clin Oncol. 2020 Jan;17(1):6. doi: 10.1038/s41571-019-0304-3.
6
Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells.mTOR抑制剂与伊立替康对结肠癌细胞的协同抗肿瘤作用
Cancers (Basel). 2019 Oct 17;11(10):1581. doi: 10.3390/cancers11101581.
7
The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells.特西罗莫司与氯喹联用可提高结直肠癌细胞的放射敏感性。
Oncol Rep. 2019 Jul;42(1):377-385. doi: 10.3892/or.2019.7134. Epub 2019 Apr 23.
8
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.阿特珠单抗联合或不联合 cobimetinib 对比regorafenib 治疗既往治疗的转移性结直肠癌（IMblaze370）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16.
9
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.阿特珠单抗联合考比替尼治疗实体瘤患者的 Ib 期研究。
Ann Oncol. 2019 Jul 1;30(7):1134-1142. doi: 10.1093/annonc/mdz113.
10
Therapeutic strategies to target RAS-mutant cancers.靶向 RAS 突变型癌症的治疗策略。
Nat Rev Clin Oncol. 2018 Nov;15(11):709-720. doi: 10.1038/s41571-018-0105-0.
Zotero 插件